Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Diabetes Prevention AI: Enhancing Prevention Strategies Using Personalized Nutrition and Fitness Coaching for the Next Generation

11 de septiembre de 2026 actualizado por: Megha Kumudchandra Shah, Emory University

This study is testing an artificial intelligence (AI) chatbot designed to help adults at risk for type 2 diabetes adopt healthier lifestyles. The chatbot provides personalized and culturally tailored guidance on nutrition, physical activity, resistance training, and goal setting. About 30 adults aged 18 to 55 years will use the chatbot for 6 weeks and provide feedback through surveys and interviews.

Researchers will evaluate whether the chatbot is easy to use, helpful, and trustworthy, and whether data about changes in health behaviors can be feasibly collected, in order to inform larger future studies to improve diabetes prevention.

Descripción general del estudio

Estado

Aún no reclutando

Descripción detallada

Type 2 diabetes continues to be a major public health concern, with growing evidence that individuals with normal body weight may also be at increased risk of developing prediabetes and type 2 diabetes. Existing diabetes prevention programs have primarily targeted individuals with overweight or obesity, creating a need for innovative prevention approaches tailored to younger, normal-weight, and culturally diverse populations.

This study will evaluate a novel artificial intelligence (AI)-powered chatbot designed to deliver personalized, culturally tailored diabetes prevention support. The intervention combines evidence-based nutrition and physical activity guidance with conversational AI technology to provide accessible lifestyle coaching focused on diabetes risk reduction. The chatbot incorporates expert-validated educational content and behavioral support strategies intended to promote healthy habits and sustained engagement.

The chatbot was developed using a curated knowledge base of culturally adapted diabetes prevention recommendations. Personalized guidance is generated using participant preferences, context, and validated educational resources to support lifestyle behaviors associated with improved metabolic health. The platform is intended to provide scalable, user-centered support while maintaining alignment with established diabetes prevention principles.

This pilot study will assess the feasibility and acceptability of implementing an AI-enabled diabetes prevention intervention in a real-world setting. Researchers will evaluate user experiences with the chatbot, including engagement, satisfaction, trust, usability, and perceptions of cultural relevance. Findings will inform future development of digital health interventions and support the design of larger studies aimed at evaluating the effectiveness of AI-assisted approaches for diabetes prevention and health equity.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

30

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Megha K Shah, M.D., M.Sc.
  • Número de teléfono: 404-778-6944
  • Correo electrónico: mkshah@emory.edu

Ubicaciones de estudio

    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Emory University

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  • Have at least one of the following diabetes risk factors:

    • HbA1C of 5.7-6.4%
    • BMI of 18.5 - 24.9 kg/m^2
    • Fasting plasma glucose 100 - 125 mg/dL
    • Family history of type 2 diabetes in first-degree relatives (parents, siblings, or children)
    • History of gestational diabetes
    • Membership in a high-risk ethnic group (African American, Hispanic, Native American, Asian American, Pacific Islander)
  • Access to a smartphone or computer with internet
  • English reading and writing proficiency
  • Be willing to use the chatbot at least 3 times per week
  • Be able to provide informed consent
  • Availability for the 6-week study duration
  • Able to perform resistance training exercises

Exclusion Criteria:

  • Are diagnosed with type 1 or type 2 diabetics
  • Have uncontrolled hypertension (higher than 160/100 mmHg)
  • Have cardiovascular disease
  • Are pregnant or planning to be pregnant
  • Are actively undergoing treatment for cancer
  • Have an eating disorder
  • Have chronic kidney disease
  • Are enrolled in another research study or participating in a structured lifestyle program

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: AI-Powered Diabetes Prevention Chatbot
Participants will receive access to an artificial intelligence (AI)-powered chatbot that provides personalized, culturally tailored diabetes prevention guidance focused on nutrition, resistance training, goal setting, and lifestyle behavior change for a 6-week intervention period.
Participants will use a generative AI chatbot designed to provide personalized, evidence-based diabetes prevention support. The chatbot delivers culturally tailored nutrition and physical activity recommendations, with an emphasis on high-protein dietary strategies, resistance training, goal setting, motivational support, and healthy lifestyle behaviors. Participants will be encouraged to interact with the chatbot at least three times per week during the 6-week study period. Recommendations are generated using expert-validated diabetes prevention content and personalized according to participant characteristics and preferences.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Feasibility and Acceptability: Task completion rate
Periodo de tiempo: Baseline, 6 weeks
The proportion of recommended chatbot activities, goals, or behavioral tasks completed by participants during the 6-week intervention period, as assessed through chatbot analytics. This measure will be used to evaluate participant engagement and adherence to chatbot-delivered recommendations.
Baseline, 6 weeks
Feasibility and Acceptability: Conversation length
Periodo de tiempo: Baseline, 6 weeks
Average number of messages exchanged between participants and the AI chatbot during each interaction session over the study period. Conversation length will be obtained from chatbot analytics and used as an indicator of participant engagement with the intervention. Longer conversations may reflect greater interaction with chatbot-delivered nutrition, physical activity, and lifestyle coaching content
Baseline, 6 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Feasibility: Body Mass Index (BMI)
Periodo de tiempo: Baseline, 6 weeks
Proportion of participants for whom self-reported body mass index (BMI, kg/m²) is successfully collected at baseline and at the end of the 6-week intervention period. BMI will be calculated using participant-reported height and weight collected through study surveys.
Baseline, 6 weeks
Feasibility: Physical Activity Behaviors
Periodo de tiempo: Baseline, 6 weeks
Proportion of participants for whom self-reported physical activity behaviors, including engagement in resistance training and overall activity levels, will be successfully collected through study questionnaires and chatbot interaction data.
Baseline, 6 weeks
Feasibility: Dietary Behaviors
Periodo de tiempo: Baseline, 6 weeks
Proportion of participants for whom self-reported dietary intake and nutrition-related behaviors, including the adoption of higher-protein dietary practices and other healthy eating behaviors promoted by the chatbot intervention, are successfully collected. Data will be collected through participant surveys and chatbot interaction records.
Baseline, 6 weeks
Feasibility: Behavioral Intention for Diabetes Prevention
Periodo de tiempo: Baseline, 6 weeks
Proportion of participants with successfully recorded self-reported intention and readiness to engage in healthy lifestyle behaviors for diabetes prevention, including dietary modifications and physical activity, as assessed through study questionnaires
Baseline, 6 weeks
Perceived Trustworthiness of the Chatbot
Periodo de tiempo: Baseline, 6 weeks
Participant-reported trust in the accuracy, reliability, and credibility of information and recommendations provided by the AI chatbot, assessed through study questionnaires.
Baseline, 6 weeks
Ease of Use: System Usability Scale (SUS)
Periodo de tiempo: Baseline
The SUS is a 10-item questionnaire that assesses participants' perceived usability of the application. Each item is rated on a 5-point response scale. Responses are scored using the standard SUS scoring method to generate a total score ranging from 0 to 100, with higher scores indicating greater perceived usability.
Baseline
NASA Task Load Index (NASA-TLX)
Periodo de tiempo: Baseline
The NASA-TLX assesses participants' perceived cognitive workload while using the application across six domains: mental demand, physical demand, temporal demand, perceived performance, effort, and frustration. An overall workload score will be calculated from the domain ratings. Scores range from 0 to 100, with higher scores indicating greater perceived workload or task demand.
Baseline

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Megha Shah, M.D., M.Sc., Emory University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de octubre de 2026

Finalización primaria (Estimado)

1 de marzo de 2027

Finalización del estudio (Estimado)

1 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

11 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

11 de septiembre de 2026

Publicado por primera vez (Actual)

17 de septiembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Marco de tiempo para compartir IPD

After study completion

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • CÓDIGO_ANALÍTICO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir